Your trusted destination for CME, CPD & Medical Education across the Middle East.
King Faisal Specialist Hospital & Research Centre
Dr. Meshari Alzahrani is a Saudi Medical Oncologist based in Riyadh and affiliated with the Department of Medical Oncology, Cancer Center of Excellence at King Faisal Specialist Hospital & Research Centre (KFSHRC). His clinical and academic work focuses on breast cancer and systemic cancer therapy, and he has contributed to Saudi national efforts to develop evidence-based recommendations for breast cancer management. His KFSHRC affiliation is confirmed in recent peer-reviewed breast-cancer research and in the 2026 Saudi breast-cancer consensus publication.
Medical Oncologist
Department of Medical Oncology, Cancer Center of Excellence
King Faisal Specialist Hospital & Research Centre (KFSHRC)
Riyadh, Saudi Arabia
His name appears among the Saudi oncology experts who participated in the national consensus statement on the management of early and metastatic breast cancer. The panel participated in the consensus meeting, Delphi voting process, manuscript development and critical review.
Dr. Alzahrani's documented work is concentrated in medical oncology, particularly breast cancer. His research involvement includes:
A 2026 Scientific Reports study lists him as a co-author on research investigating tocilizumab combined with cisplatin/docetaxel for locally advanced triple-negative breast cancer, with all oncology authors affiliated with KFSHRC's Cancer Center of Excellence.
One of his recent major academic contributions is the 2026 publication:
“Management of Early and Metastatic Breast Cancer: A Consensus Statement from Oncologists in Saudi Arabia.”
Dr. Alzahrani was one of the Saudi oncology experts participating in the Delphi consensus process. The panel reached agreement on 13 recommendations for early breast cancer and seven recommendations for metastatic breast cancer, providing guidance for physicians treating breast cancer in Saudi Arabia.
He is also a co-author of the 2026 Scientific Reports paper:
“Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial.” The paper lists his affiliation as the Department of Medical Oncology, Cancer Center of Excellence, KFSHRC, Riyadh.
His research record also includes work involving trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer in Saudi Arabia. He is listed as a KFSHRC author on the corresponding ASCO publication.
Dr. Alzahrani is part of the group of Saudi oncologists contributing to the development of national breast-cancer treatment recommendations. His participation in the consensus process demonstrates involvement not only in clinical oncology but also in multidisciplinary expert discussions concerning modern breast-cancer treatment.
The consensus work was supported by the Medical Oncology Department of the Cancer Center of Excellence at KFSHRC, in connection with the 2025 KFSHRC Breast Cancer
